{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:51:11Z","timestamp":1792839071332,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1053\/j.ajkd.2011.07.017","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T14:39:00Z","timestamp":1317393540000},"page":"928-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Therapeutic Response to Vasoconstrictors in Hepatorenal Syndrome Parallels Increase in Mean Arterial Pressure: A Pooled Analysis of Clinical Trials"],"prefix":"10.1053","volume":"58","author":[{"given":"Juan Carlos Q.","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Nietert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2011.07.017_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9343(70)80073-0","article-title":"Renal failure in the patient with cirrhosis","volume":"49","author":"Epstein","year":"1970","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gines","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/00365517709100657","article-title":"Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function","volume":"37","author":"Ring-Larsen","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1053\/j.ajkd.2011.07.017_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jhep.2007.02.001","article-title":"Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome","volume":"46","author":"Arroyo","year":"2007","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000142939","article-title":"Acute kidney injury: new concepts","volume":"109","author":"Moreau","year":"2008","journal-title":"Nephron Physiol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib6","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1345\/aph.1H373","article-title":"Terlipressin: vasopressin analog and novel drug for septic shock","volume":"40","author":"Pesaturo","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ajkd.2011.07.017_bib7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.ajkd.2011.07.017_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","author":"Boyer","year":"2011","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib10","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib11","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.ajkd.2011.07.017_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.dld.2008.09.014","article-title":"Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study","volume":"41","author":"Alessandria","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.ajkd.2011.07.017_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.30.1.90","article-title":"Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis","volume":"30","author":"Lenz","year":"1989","journal-title":"Gut"},{"key":"10.1053\/j.ajkd.2011.07.017_bib15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/0016-5085(91)90734-3","article-title":"Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis","volume":"101","author":"Lenz","year":"1991","journal-title":"Gastroenterology"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2011.07.017_bib16","first-page":"ccciii","article-title":"Terlipressin and albumin combination treatment in hepatorenal syndrome","volume":"50","author":"Danalioglu","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2796.1999.00556.x","article-title":"Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure","volume":"246","author":"Eisenman","year":"1999","journal-title":"J Intern Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.ajkd.2011.07.017_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0168-8278(99)80025-7","article-title":"Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients","volume":"30","author":"Kaffy","year":"1999","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1590\/S0004-28032009000300014","article-title":"Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature","volume":"46","author":"Kalil","year":"2009","journal-title":"Arq Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study","volume":"20","author":"Kiser","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2011.07.017_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MEG.0b013e3283345524","article-title":"Terlipressin therapy for renal failure in cirrhosis","volume":"22","author":"Triantos","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0028-1109084","article-title":"Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study","volume":"47","author":"von Kalckreuth","year":"2009","journal-title":"Z Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib26","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/j.1572-0241.2000.03214.x","article-title":"Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?","volume":"95","author":"Duhamel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","article-title":"Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study","volume":"14","author":"Halimi","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Martin-Llahi","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.ajkd.2011.07.017_bib32","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib36","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib37","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/j.ajkd.2011.07.017_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib39","first-page":"78","article-title":"Terlipressin and gelafundin: safe therapy of hepatorenal syndrome","volume":"9","author":"Saner","year":"2004","journal-title":"Eur J Med Res"},{"key":"10.1053\/j.ajkd.2011.07.017_bib40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib42","first-page":"1053","article-title":"[Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]","volume":"36","author":"Gulberg","year":"1998","journal-title":"Z Gastroenterol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1665-2681(19)31767-3","article-title":"Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin","volume":"8","author":"Munoz","year":"2009","journal-title":"Ann Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2","volume":"14","author":"Alessandria","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.mcna.2009.03.003","article-title":"Renal failure in patients with cirrhosis","volume":"93","author":"Mackelaite","year":"2009","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ajkd.2011.07.017_bib47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials","volume":"25","author":"Sagi","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib50","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00003246-199907000-00031","article-title":"Microcirculatory oxygenation and shunting in sepsis and shock","volume":"27","author":"Ince","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis","volume":"134","author":"Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/cc1052","article-title":"Noradrenaline and the kidney: friends or foes?","volume":"5","author":"Bellomo","year":"2001","journal-title":"Crit Care"},{"key":"10.1053\/j.ajkd.2011.07.017_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.01820407","article-title":"Approach to hemodynamic shock and vasopressors","volume":"3","author":"Herget-Rosenthal","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/01.CCM.0000157788.20591.23","article-title":"Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function","volume":"33","author":"Bourgoin","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib56","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1097\/00003246-200008000-00007","article-title":"Effects of perfusion pressure on tissue perfusion in septic shock","volume":"28","author":"LeDoux","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib57","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM196906192802501","article-title":"Transplantation of cadaveric kidneys from patients with hepatorenal syndrome","volume":"280","author":"Koppel","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2011.07.017_bib58","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2011.07.017_bib59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1476-5381.1985.tb16154.x","article-title":"The role of alpha-adrenoceptors in the regulation of renal tubular sodium reabsorption and renin secretion in the rabbit","volume":"84","author":"Hesse","year":"1985","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ki.2010.323","article-title":"Do meta-analyses in nephrology change the way we treat patients?","volume":"78","author":"Mohan","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2011.07.017_bib61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0168-8278(96)80297-2","article-title":"Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome","volume":"25","author":"Salo","year":"1996","journal-title":"J Hepatol"},{"key":"10.1053\/j.ajkd.2011.07.017_bib62","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1378\/chest.126.2.534","article-title":"Renal effects of norepinephrine in septic and nonseptic patients","volume":"126","author":"Albanese","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.ajkd.2011.07.017_bib63","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1378\/chest.103.6.1826","article-title":"Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?","volume":"103","author":"Martin","year":"1993","journal-title":"Chest"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611011929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611011929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:58:45Z","timestamp":1759456725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638611011929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0272638611011929"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2011.07.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Response to Vasoconstrictors in Hepatorenal Syndrome Parallels Increase in Mean Arterial Pressure: A Pooled Analysis of Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2011.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}